ID   TOV-1369
AC   CVCL_9T17
SY   TOV-1369 TR; TOV-1369TR; TOV1369; OVCA1369_TR
DR   cancercelllines; CVCL_9T17
DR   GEO; GSM2475006
DR   Wikidata; Q54972797
RX   PubMed=22585861;
RX   PubMed=22931248;
RX   PubMed=28273451;
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=OVCA1369_TR
CC   Doubling time: 2.87 +- 0.03 days (PubMed=22931248).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Cys (c.730G>T); ClinVar=VCV000376599; Zygosity=Unspecified (PubMed=22931248; PubMed=28273451).
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: STR profile from personal communication of Mes-Masson A.-M.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,11
ST   D16S539: 11,13
ST   D21S11: 30,31
ST   D5S818: 13
ST   D7S820: 11
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_9T12 ! OV-1369(R2)
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 05-10-23; Version: 11
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=22931248; DOI=10.1186/1471-2407-12-379;
RA   Letourneau I.J., Quinn M.C.J., Wang L.-L., Portelance L., Caceres K.Y.,
RA   Cyr L., Delvoye N., Meunier L., de Ladurantaye M., Shen Z.,
RA   Arcand S.L., Tonin P.N., Provencher D.M., Mes-Masson A.-M.;
RT   "Derivation and characterization of matched cell lines from primary
RT   and recurrent serous ovarian cancer.";
RL   BMC Cancer 12:379.1-379.16(2012).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//